上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (11): 1536-.doi: 10.3969/j.issn.1674-8115.2011.11.007

• 专题报道（双相障碍） • 上一篇    下一篇

碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性

粟幼嵩, 陈 俊, 李则挚, 王 勇, 黄 佳, 方贻儒, 王祖承   

  1. 上海交通大学 医学院附属精神卫生中心心境障碍科, 上海 200030
  • 出版日期:2011-11-28 发布日期:2011-11-29
  • 作者简介:粟幼嵩（1981—）, 男, 住院医师, 硕士；电子信箱: wintersus@126.com。
  • 基金资助:

    国家自然科学基金（30971047）；国家高技术研究发展计划（“八六三”计划）（2006AA02Z430）；“十五”国家科技攻关计划（2004BA720A21-02）；上海交通大学医学院“重点学科建设”基金（沪交医科[2008]-6）；上海交通大学医学院自然科学基金（09XJ21024）；上海市精神卫生中心院级课题（2010-YJ-03）

Clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression

SU You-song, CHEN Jun, LI Ze-zhi, WANG Yong, HUANG Jia, FANG Yi-ru, WANG Zu-bcheng   

  1. Department of Mood Disorder, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China
  • Online:2011-11-28 Published:2011-11-29
  • Supported by:

    National Natural Science Foundation of China, 30971047；National High Technology Research and Development Program of China, “863” Program, 2006AA02Z430；National Key Technology Research and Development Program of China in “Tenth-Five Year Plan”, 2004BA720A21-02；Shanghai Jiaotong University School of Medicine Foundation, 2008-6, 09XJ21024；Shanghai Mental Health Center Foundation, 2010-YJ-03

PDF (PC)

3496

摘要：

目的 探讨碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性。方法 81例双相障碍抑郁发作患者随机分为联合用药组（n=42）和锂盐组（n=39），分别给予碳酸锂联合阿立哌唑治疗或单用碳酸锂治疗，持续8周。在基线期及治疗第1、2、4、8周末，采用17项汉密顿抑郁量表(HAMD-17)和Young躁狂评定量表（YMRS）评定疗效，计算治疗有效率，采用治疗时出现的症状量表（TESS）评定不良反应。结果 基线期两组HAMD-17评分差异无统计学意义（P>0.05），治疗第1、2、4周末联合用药组HAMD-17评分显著低于锂盐组（P<0.05或 P<0.01）；治疗第8周末联合用药组HAMD-17评分低于锂盐组，但差异无统计学意义（P>0.05）。两组基线期及治疗各阶段的YMRS评分均<7。两组治疗有效率和不良反应发生率比较差异均无统计学意义(P>0.05)。结论 与单用碳酸锂比较，碳酸锂联合阿立哌唑治疗双相障碍抑郁发作起效快，疗效相似，不良反应无明显增加。

关键词: 阿立哌唑, 双相障碍抑郁发作, 疗效, 安全性

Abstract:

Objective To investigate the clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression. Methods Eighty-one patients with bipolar depression were randomly divided into lithium carbonate combined with aripiprazole group (n=42) or lithium carbonate group (n=39), and were treated with lithium carbonate combined with aripiprazole and lithium carbonate for 8 weeks respectively. At the baseline and the end of fthe irst, second, fourth and eighth week of treatment, Hamilton Depression Scale-17 (HAMD-17) and Young Mania Rating Scale (YMRS) were employed to evaluate the clinical efficacy, the effective rates were calculated, and Treatment Emergent Symptom Scale (TESS) was adopted to assess the side effects. Results There was no significant difference in HAMD-17 score between two group at the baseline (P>0.05), while HAMD-17 scores at the end of first, second and fourth week of treatment in lithium carbonate combined with aripiprazole group were significantly lower than those in lithium carbonate group (P<0.05 or P<0.01). Though HAMD-17 score at the end of the eighth week of treatment in lithium carbonate combined with aripiprazole group was lower than that in lithium carbonate group, there was no significant difference between two groups (P>0.05). All the scores of YMRS at the baseline and the end of the first, second, fourth and eighth week of treatment were lower than 7. There was no significant difference in the effective rate and prevalence of side effects between two groups (P>0.05). Conclusion Compared with lithium carbonate, lithium carbonate combined with aripiprazole may have earlier effects, similar clinical efficacy and no more side effects in treatment of bipolar depression.

Key words: aripiprazole, bipolar depression, efficacy, safety